Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Idelalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 25,846Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Paragraph IV Patent Litigation for Idelalisib.
    FDA Confirms Paragraph IV Patent Litigation for Idelalisib.

    05 May 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-idelalisib-1652172175.pdf

    FDA
    05 May 2022
    Share Share
    Incyte pulls approval filing, following Gilead out of the exitIn
    Incyte pulls approval filing, following Gilead out of the exitIn

    27 Jan 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/incyte-pulls-fda-filing-for-cancer-drug-approval-over-confirmatory-study-following-gilead

    N.P. Taylor FIERCEBIOTECH
    27 Jan 2022
    Share Share
    Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials
    Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials

    24 Jan 2022

    // Hayley Shasteen BIOSPACE

    https://www.biospace.com/article/gilead-withdraws-cancer-drug-amidst-uncompleted-follow-up-trials-/

    Hayley Shasteen BIOSPACE
    24 Jan 2022
    Share Share
    Gilead pulls 2 accelerated approval indications for cancer drug
    Gilead pulls 2 accelerated approval indications for cancer drug

    22 Jan 2022

    // Z. Brennan ENDPTS

    https://endpts.com/failing-to-confirm-clinical-benefit-gilead-pulls-2-accelerated-approval-indications-for-cancer-drug/

    Z. Brennan ENDPTS
    22 Jan 2022
    Share Share
    Gilead withdraws use of Zydelig to treat two types of cancer
    Gilead withdraws use of Zydelig to treat two types of cancer

    15 Jan 2022

    // Leroy Leo REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-withdraws-use-zydelig-treat-two-types-cancer-2022-01-14/

    Leroy Leo REUTERS
    15 Jan 2022
    Share Share
    TG Therapeutics wins FDA nod for potentially safer Zydelig rival
    TG Therapeutics wins FDA nod for potentially safer Zydelig rival

    09 Feb 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/marketing/watch-out-gilead-tg-therapeutics-has-won-fda-nod-for-a-potentially-safer-pi3k-drug-than

    Angus Liu FIERCEPHARMA
    09 Feb 2021
    Share Share